BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santa-Cecília FV, Leite CA, Del-Bel E, Raisman-Vozari R. The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases. Neurotox Res 2019;35:981-6. [PMID: 30798507 DOI: 10.1007/s12640-019-00015-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Pan Y, Chen YX, Zhang J, Lin ML, Liu GM, Xu XL, Fan XQ, Zhong Y, Li Q, Ai SM, Xu W, Tan J, Zhou HF, Xu DD, Zhang HY, Xu B, Wang S, Ma JJ, Zhang S, Gan LY, Cui JT, Li L, Xie YY, Guo X, Pan-Doh N, Zhu ZT, Lu Y, Shi YX, Xia YW, Li ZY, Liang D. Doxycycline vs Placebo at 12 Weeks in Patients With Mild Thyroid-Associated Ophthalmopathy: A Randomized Clinical Trial. JAMA Ophthalmol 2022. [PMID: 36173609 DOI: 10.1001/jamaophthalmol.2022.3779] [Reference Citation Analysis]
2 Fan G, Chen S, Tao Z, Zhang H, Yu R. A novel small positive allosteric modulator of neuropeptide receptor PAC1-R exerts neuroprotective effects in MPTP mouse Parkinson's disease model. Acta Biochim Biophys Sin (Shanghai) 2022. [PMID: 36082935 DOI: 10.3724/abbs.2022126] [Reference Citation Analysis]
3 Suárez-Rivero JM, Pastor-Maldonado CJ, Povea-Cabello S, Álvarez-Córdoba M, Villalón-García I, Talaverón-Rey M, Suárez-Carrillo A, Munuera-Cabeza M, Reche-López D, Cilleros-Holgado P, Piñero-Perez R, Sánchez-Alcázar JA. UPRmt activation improves pathological alterations in cellular models of mitochondrial diseases. Orphanet J Rare Dis 2022;17:204. [PMID: 35581596 DOI: 10.1186/s13023-022-02331-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Feitosa RC, Ishikawa ESA, Silva MFAD, Silva-júnior AAD, Oliveira-nascimento L. Five decades of doxycycline: Does nanotechnology improve its properties? International Journal of Pharmaceutics 2022;618:121655. [DOI: 10.1016/j.ijpharm.2022.121655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gomez-Murcia V, Carvalho K, Thiroux B, Caillierez R, Besegher M, Sergeant N, Buée L, Faivre E, Blum D. Impact of chronic doxycycline treatment in the APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology 2022;:108999. [PMID: 35181375 DOI: 10.1016/j.neuropharm.2022.108999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Klann EM, Dissanayake U, Gurrala A, Farrer M, Shukla AW, Ramirez-zamora A, Mai V, Vedam-mai V. The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review. Front Aging Neurosci 2022;13:782082. [DOI: 10.3389/fnagi.2021.782082] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
7 Markulin I, Matasin M, Turk VE, Salković-Petrisic M. Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease. J Neural Transm (Vienna) 2022. [PMID: 34982206 DOI: 10.1007/s00702-021-02457-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lavigna G, Masone A, Bouybayoune I, Bertani I, Lucchetti J, Gobbi M, Porcu L, Zordan S, Rigamonti M, Imeri L, Restelli E, Chiesa R. Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice. Neurobiol Dis 2021;158:105455. [PMID: 34358614 DOI: 10.1016/j.nbd.2021.105455] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Marjani S, Zirh S, Sever-Bahcekapili M, Cakir-Aktas C, Muftuoglu SF, Mut M. Doxycycline alleviates acute traumatic brain injury by suppressing neuroinflammation and apoptosis in a mouse model. J Neuroimmunol 2021;359:577672. [PMID: 34364104 DOI: 10.1016/j.jneuroim.2021.577672] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Mansour NO, Shama MA, Werida RH. The effect of doxycycline on neuron-specific enolase in patients with traumatic brain injury: a randomized controlled trial. Ther Adv Chronic Dis 2021;12:20406223211024362. [PMID: 34262678 DOI: 10.1177/20406223211024362] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Bortolanza M, do Nascimento GC, Raisman-Vozari R, Del-Bel E. Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats. Br J Pharmacol 2021;178:2595-616. [PMID: 33751546 DOI: 10.1111/bph.15439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Dominguez-Meijide A, Parrales V, Vasili E, González-Lizárraga F, König A, Lázaro DF, Lannuzel A, Haik S, Del Bel E, Chehín R, Raisman-Vozari R, Michel PP, Bizat N, Outeiro TF. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo. Neurobiol Dis 2021;151:105256. [PMID: 33429042 DOI: 10.1016/j.nbd.2021.105256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
13 Park CS, Kim SH, Lee CK. Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines. Immune Netw 2020;20:e47. [PMID: 33425432 DOI: 10.4110/in.2020.20.e47] [Reference Citation Analysis]
14 Binvignat O, Olloquequi J. Excitotoxicity as a Target Against Neurodegenerative Processes. Curr Pharm Des 2020;26:1251-62. [PMID: 31931694 DOI: 10.2174/1381612826666200113162641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
15 Afshari K, Momeni Roudsari N, Lashgari NA, Haddadi NS, Haj-Mirzaian A, Hassan Nejad M, Shafaroodi H, Ghasemi M, Dehpour AR, Abdolghaffari AH. Antibiotics with therapeutic effects on spinal cord injury: a review. Fundam Clin Pharmacol 2021;35:277-304. [PMID: 33464681 DOI: 10.1111/fcp.12605] [Reference Citation Analysis]
16 Xu J, Zhao C, Huang X, Du W. Tetracycline derivatives resist the assembly behavior of human islet amyloid polypeptide. Biochimie 2020;174:95-106. [DOI: 10.1016/j.biochi.2020.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
17 Crabbe JC, Ozburn AR, Hitzemann RJ, Spence SE, Hack WR, Schlumbohm JP, Metten P. Tetracycline derivatives reduce binge alcohol consumption in High Drinking in the Dark mice. Brain Behav Immun Health 2020;4:100061. [PMID: 34589846 DOI: 10.1016/j.bbih.2020.100061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Pathak S, Tripathi S, Deori N, Ahmad B, Verma H, Lokhande R, Nagotu S, Kale A. Effect of tetracycline family of antibiotics on actin aggregation, resulting in the formation of Hirano bodies responsible for neuropathological disorders. J Biomol Struct Dyn 2021;39:236-53. [PMID: 31948361 DOI: 10.1080/07391102.2020.1717629] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Moszczynski AJ, Harvey M, Fulcher N, de Oliveira C, McCunn P, Donison N, Bartha R, Schmid S, Strong MJ, Volkening K. Synergistic toxicity in an in vivo model of neurodegeneration through the co-expression of human TDP-43M337V and tauT175D protein. Acta Neuropathol Commun 2019;7:170. [PMID: 31703746 DOI: 10.1186/s40478-019-0816-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
20 Gazerani P. Probiotics for Parkinson's Disease. Int J Mol Sci 2019;20:E4121. [PMID: 31450864 DOI: 10.3390/ijms20174121] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
21 Balducci C, Forloni G. Doxycycline for Alzheimer's Disease: Fighting β-Amyloid Oligomers and Neuroinflammation. Front Pharmacol 2019;10:738. [PMID: 31333460 DOI: 10.3389/fphar.2019.00738] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]